Yaw A Nyame1, Adam B Murphy2, Diana K Bowen1, Gregory Jordan1, Ken Batai1, Michael Dixon1, Courtney M P Hollowell1, Stephanie Kielb1, Joshua J Meeks1, Peter H Gann1, Virgilia Macias1, Andre Kajdacsy-Balla1, William J Catalona1, Rick Kittles1. 1. Yaw A. Nyame, Cleveland Clinic, Cleveland, Ohio; Adam B. Murphy, Diana K. Bowen, Gregory Jordan, Michael Dixon, Stephanie Kielb, Joshua J. Meeks, and William J. Catalona, Northwestern University, Chicago; Courtney M.P. Hollowell, Cook County Health and Hospitals System; Peter H. Gann, Virgilia Macias, and Andre Kajdacsy-Balla, University of Illinois at Chicago, Chicago, IL; and Ken Batai and Rick Kittles, University of Arizona, Tucson, AZ. 2. Yaw A. Nyame, Cleveland Clinic, Cleveland, Ohio; Adam B. Murphy, Diana K. Bowen, Gregory Jordan, Michael Dixon, Stephanie Kielb, Joshua J. Meeks, and William J. Catalona, Northwestern University, Chicago; Courtney M.P. Hollowell, Cook County Health and Hospitals System; Peter H. Gann, Virgilia Macias, and Andre Kajdacsy-Balla, University of Illinois at Chicago, Chicago, IL; and Ken Batai and Rick Kittles, University of Arizona, Tucson, AZ. a-murphy2@northwestern.edu.
Abstract
PURPOSE: Lower serum vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels. METHODS: This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. RESULTS: Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. The median age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) compared with their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01). CONCLUSION: Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.
PURPOSE: Lower serum vitamin D levels have been associated with an increased risk of aggressive prostate cancer. Among men with localized prostate cancer, especially with low- or intermediate-risk disease, vitamin D may serve as an important biomarker of disease aggression. The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels. METHODS: This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening. In total, 190 men underwent radical prostatectomy in the cohort. Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension. Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy. RESULTS: Eighty-seven men (45.8%) in this cohort demonstrated adverse pathology at radical prostatectomy. The median age in the cohort was 64.0 years (interquartile range, 59.0 to 67.0). On univariate analysis, men with adverse pathology at radical prostatectomy demonstrated lower median serum 25-OH D (22.7 v 27.0 ng/mL, P = .007) compared with their counterparts. On multivariate analysis, controlling for age, serum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 ng/mL was associated with increased odds of adverse pathology (odds ratio, 2.64; 95% CI, 1.25 to 5.59; P = .01). CONCLUSION:Insufficiency/deficiency of serum 25-OH D is associated with increased odds of adverse pathology in men with localized disease undergoing radical prostatectomy. Serum 25-OH D may serve as a useful biomarker in prostate cancer aggressiveness, which deserves continued study.
Authors: Ruth D Etzioni; Nadia Howlader; Pamela A Shaw; Donna P Ankerst; David F Penson; Phyllis J Goodman; Ian M Thompson Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: G J Miller; G E Stapleton; J A Ferrara; M S Lucia; S Pfister; T E Hedlund; P Upadhya Journal: Cancer Res Date: 1992-02-01 Impact factor: 12.701
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: J I Epstein; D W Chan; L J Sokoll; P C Walsh; J L Cox; H Rittenhouse; R Wolfert; H B Carter Journal: J Urol Date: 1998-12 Impact factor: 7.450
Authors: Ken Batai; Adam B Murphy; Maria Ruden; Jennifer Newsome; Ebony Shah; Michael A Dixon; Elizabeth T Jacobs; Courtney M P Hollowell; Chiledum Ahaghotu; Rick A Kittles Journal: BMC Cancer Date: 2017-01-19 Impact factor: 4.430
Authors: A B Murphy; Y A Nyame; K Batai; R Kalu; A Khan; P Gogana; M Dixon; V Macias; A Kajdacsy-Balla; C M P Hollowell; W J Catalona; R Kittles Journal: Prostate Cancer Prostatic Dis Date: 2016-10-11 Impact factor: 5.554
Authors: Lucas Tricoli; Aisha Naeem; Erika Parasido; John P Mikhaiel; Muhammad Umer Choudhry; Deborah L Berry; Iman A Abdelgawad; Richard J Lee; Adam S Feldman; Chukwuemeka Ihemelandu; Maria Avantaggiati; Deepak Kumar; Stephen Byers; Rosa Gallagher; Julia Wulfkuhle; Emanuel Petricoin; Olga Rodriguez; Chris Albanese Journal: Oncotarget Date: 2017-12-18
Authors: Kimberly L Santucci; John M Baust; Kristi K Snyder; Robert G Van Buskirk; John G Baust Journal: Cancer Control Date: 2018 Jan-Mar Impact factor: 3.302